Mitochondrial myopathy and sideroblastic anemia

Mitochondrial myopathy and sideroblastic anemia (MLASA), also known as myopathy, lactic acidosis, and sideroblastic anemia, is a rare inherited metabolic disorder caused by defects in mitochondrial function. The condition primarily affects skeletal muscles and the blood-forming (hematopoietic) system. It is characterized by progressive exercise intolerance and muscle weakness (myopathy) due to impaired mitochondrial energy production in muscle cells, combined with sideroblastic anemia — a type of anemia in which the bone marrow produces ringed sideroblasts (red blood cell precursors with iron-laden mitochondria) rather than healthy red blood cells. Patients typically also experience lactic acidosis, a buildup of lactic acid in the blood resulting from defective mitochondrial oxidative phosphorylation. The disease has been associated with mutations in several genes, most notably PUS1 (pseudouridylate synthase 1) and YARS2 (mitochondrial tyrosyl-tRNA synthetase), both of which play critical roles in mitochondrial protein synthesis. Mutations in these genes lead to impaired translation of mitochondrial-encoded proteins essential for the electron transport chain. Onset is typically in childhood or adolescence, though variability exists. Affected individuals may present with fatigue, exercise intolerance, progressive proximal muscle weakness, and pallor or other signs of anemia. Muscle biopsy often reveals ragged-red fibers and cytochrome c oxidase-deficient fibers, hallmarks of mitochondrial myopathy. Treatment is largely supportive and symptomatic. Management of anemia may include blood transfusions and, in some cases, iron chelation therapy to prevent iron overload. Supplementation with cofactors such as coenzyme Q10, riboflavin, and other mitochondrial supplements has been tried, though evidence for efficacy remains limited. Physical therapy may help maintain muscle function. Prognosis varies depending on the severity of the mitochondrial dysfunction, and the condition can be progressive. Genetic counseling is recommended for affected families.

Common questions about Mitochondrial myopathy and sideroblastic anemia